Outro
Healthcare technology company focused on medically supervised deprescribing of psychiatric medications.
Website: https://outro.com
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Outro |
| Tagline | Healthcare technology company focused on medically supervised deprescribing of psychiatric medications. |
| Headquarters | New York, United States [Morningstar, October 2026] |
| Founded | 2022 [Wired, June 2025] |
| Stage | Seed [Morningstar, October 2026] |
| Business model | B2C |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+), Brandon Goode, Dr. Mark Horowitz, Tyler Dyck [Wired, June 2025] [MobiHealthNews, October 2026] |
| Funding label | Seed, total disclosed approximately $7,000,000 [Morningstar, October 2026] [Citybiz, October 2026] |
Links
Publicly reported
- Website: https://www.outro.com
Summary and Signal
PUBLIC Outro is a virtual care company focused on medically supervised antidepressant tapering, and it merits attention now because it has paired a narrowly defined clinical use case with newly announced seed-stage financing and a growing multistate footprint [Wired, June 2025] [Morningstar, October 2026] [Citybiz, October 2026]. Founded in 2022, the company was co-founded by Brandon Goode, Dr. Mark Horowitz, and Tyler Dyck, with Horowitz's published work on antidepressant withdrawal and hyperbolic tapering giving the clinical thesis more substance than is typical for an early consumer health service [Wired, June 2025] [outro.com, retrieved 2026] [luma.com, retrieved 2026].
The product, marketed as Taper Management, connects patients with clinicians for personalized tapering plans, ongoing monitoring, dose adjustments, and clinical support; public reporting and company materials also point to custom or compounded medication as part of the care model [MobiHealthNews, October 2026] [outro.com, retrieved 2026]. That positioning matters because the differentiation appears to sit less in software alone and more in translating a clinically contentious, operationally difficult deprescribing process into a repeatable virtual-care workflow, with pricing starting at $125 per month according to Wired's 2025 launch coverage [Wired, June 2025].
On team quality, the public record is strongest around Horowitz's domain expertise and the founders' prior overlap at Field Trip Health, while Goode's background is reported to include market access and strategic partnerships work and Dyck is identified as another Field Trip alumnus [Wired, June 2025] [success.ai, retrieved 2026] [marketscreener.com, retrieved 2026]. Financing remains early but credible: Outro announced $7 million in combined pre-seed and seed funding in October 2026, with participation from Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group, and Pave Health Ventures, though round-by-round allocation and lead investor were not disclosed in the cited coverage [Morningstar, October 2026] [Citybiz, October 2026] [Pulse 2.0, October 2026].
The business model reads as B2C telehealth today, and the near-term watchpoints are straightforward: whether the company can convert a seven-state launch in 2025 into durable coverage across 14 states by late 2026, broaden beyond antidepressants without diluting clinical quality, and show that clinician-guided tapering can scale operationally rather than remain a high-touch niche service [prweb.com, May 2025] [Citybiz, October 2026] [MobiHealthNews, October 2026]. Public materials also reference plans for AI-assisted clinical workflows, but the investable question over the next 12 to 18 months is execution, not tooling: state expansion, patient acquisition efficiency at a $125 starting price point, and evidence that outcomes and patient satisfaction hold as the clinician network grows [Morningstar, October 2026] [Wired, June 2025].
One source, partially checked -- This section relies on named public reporting and company materials, with several core facts corroborated across two sources, but product detail and some team background remain only partially independently verified.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed, total disclosed about $7,000,000 |
Company Overview
PUBLIC
Outro presents as a young telehealth company built around a narrow, clinically specific problem: helping patients taper off antidepressants under supervision rather than leaving discontinuation to ad hoc primary care follow-up or self-management. Public company profiles place the business in New York and show a 2022 founding date under the Outro or Outro Health name, which aligns with the company website's positioning around personalized antidepressant tapering care [Crunchbase] [outro.com, retrieved 2026].
The public record is still thin on formal corporate history, and that matters because chronology is doing much of the interpretive work here. The clearest operating milestone in public sources is the company's website describing a live virtual care service for antidepressant taper management as of 2026, while Crunchbase reflects the company as an active venture-backed startup founded in 2022 [outro.com, retrieved 2026] [Crunchbase]. In practice, that leaves a simple sequence: founding in 2022, product positioning around supervised antidepressant tapering thereafter, and a still-early company profile with limited public legal-entity detail in the sources reviewed [Crunchbase] [outro.com, retrieved 2026].
One source, partially checked -- Confirmed primarily by Crunchbase and the company website; legal-entity detail and fuller milestone history were not corroborated by additional cited public filings in the provided source set.
The Product and the Stack
MIXED
The product is best understood as a virtual clinical service first, with software in support of care delivery rather than as the end product itself. Public reporting and company materials describe Outro as a personalized antidepressant tapering service that connects patients with clinicians, begins with an initial evaluation, and continues through monitoring, dose adjustments, and clinical support [Wired, June 2025] [MobiHealthNews, October 2026] [outro.com, retrieved 2026]. Outro says its current offering is Taper Management for antidepressant medications, and company materials frame the approach around science-based tapering intended to reduce withdrawal symptoms [outro.com, retrieved 2026].
The operating detail that matters is that the service bundle appears to include both clinical supervision and medication-management logistics. Outro states that it provides hyperbolic dose reductions, custom medications, and clinician support, while MobiHealthNews reports a virtual care model with ongoing monitoring and dose adjustments [outro.com, retrieved 2026] [MobiHealthNews, October 2026]. Wired reported in June 2025 that pricing started at $125 per month, which places the product closer to a recurring care program than a one-time consultation [Wired, June 2025].
Publicly announced expansion plans are still adjacent to the core tapering workflow, which keeps the product story fairly coherent at this stage. In October 2026 coverage of the financing, Outro said it planned to use new capital to expand beyond antidepressants and support AI-enabled or AI-assisted clinical workflows, alongside growth in its clinician network [Morningstar, October 2026] [Citybiz, October 2026] [Pulse 2.0, October 2026]. That said, the available public evidence does not verify the underlying software stack, degree of automation, or whether any AI tooling is already in production, so those claims are best treated as announced direction rather than demonstrated capability [Morningstar, October 2026] [Citybiz, October 2026].
One source, partially checked -- Core product scope is corroborated by Wired, MobiHealthNews, and company materials, but technology implementation detail remains limited and some forward-looking claims are company-announced rather than independently verified.
The Market They Are Entering
PUBLIC
The market matters now because antidepressant use is widespread, tapering remains clinically complex, and public coverage suggests patients are increasingly seeking structured help rather than informal self-management [Wired, June 2025] [Business Insider, October 2026].
Public evidence does not support a clean TAM, SAM, or SOM for Outro itself, and the available reporting does not cite a named third-party market report specific to antidepressant deprescribing services. What the record does show is a narrower but tangible access story: Outro launched its antidepressant tapering service in seven U.S. states by May 2025 and reported availability in 14 states by October 2026 [prweb.com, May 2025] [Citybiz, October 2026]. That is not a market size estimate, but it is a useful proxy for early geographic expansion in a category where licensure, clinician supply, and pharmacy logistics can constrain service coverage [MobiHealthNews, October 2026].
Demand appears to be driven by the gap between long-term psychiatric medication use and the limited infrastructure for supervised discontinuation. Wired's June 2025 profile described Outro as a U.S. launch built around helping people get off antidepressants, with pricing starting at $125 per month, which implies management sees enough consumer willingness to pay for a direct-to-patient service rather than waiting for payer-led adoption [Wired, June 2025]. By October 2026, MobiHealthNews and Business Insider both described a care model centered on clinician-guided dose reduction, monitoring, and adjustment, reinforcing the view that the category is not simply digital content or coaching, but a higher-touch virtual care workflow [MobiHealthNews, October 2026] [Business Insider, October 2026].
The closest adjacent markets are broader telepsychiatry, medication management, compounding-enabled specialty care, and behavioral health navigation. Outro's current positioning is more specific than any of those, focused on taper management for antidepressants rather than general mental health treatment [outro.com, retrieved 2026] [MobiHealthNews, October 2026]. The practical substitute today is often standard outpatient psychiatry or primary care, where dose reduction may be handled episodically rather than through a dedicated tapering protocol, though the cited sources do not quantify how often that substitute is sufficient [Wired, June 2025].
Regulation and macro conditions cut both ways. Telehealth remains the obvious enabler because Outro's model depends on remote clinician access and ongoing follow-up across multiple states [MobiHealthNews, October 2026]. At the same time, the service appears to rely in part on custom or compounded medication for gradual dose reductions, which can add operational and regulatory complexity depending on state rules, prescribing practices, and pharmacy execution; the cited coverage supports the presence of compounded medication in the model, but does not detail reimbursement or pharmacy economics [outro.com, retrieved 2026].
| Cited market signal | What it indicates | Source |
|---|---|---|
| Service launched in 7 U.S. states by May 2025 | Early licensed-service footprint and initial go-to-market scope | [prweb.com, May 2025] |
| Taper Management available in 14 states by October 2026 | Expanded geographic reach within roughly 17 months | [Citybiz, October 2026] |
| Pricing starts at $125 per month | Consumer willingness-to-pay test in a B2C model | [Wired, June 2025] |
The table does not size the market, but it does frame the opportunity in operational terms. The main signal is that demand may be real enough to support paid consumer uptake and measured state-by-state expansion, while the category still looks early and supply-constrained rather than broadly standardized.
One source, partially checked -- This section relies on named public reporting and company materials, but it does not have third-party market sizing specific to antidepressant deprescribing services.
The Competitive Field
MIXED Outro is positioning itself less against a single telehealth rival than against a fragmented set of alternatives: standard psychiatric care, primary care deprescribing, self-managed tapering, and information communities that patients already use when formal support falls short [Wired, June 2025] [MobiHealthNews, October 2026].
The clearest public map starts with incumbents and substitutes, because named startup peers are not established in the source set. On one side sit psychiatrists and primary care clinicians who already control prescribing and can supervise dose reductions inside conventional care settings, even if tapering protocols are not their explicit commercial focus [Wired, June 2025]. On another side are adjacent substitutes such as peer forums, educational resources, and patient-led tapering practices, which Wired and Business Insider both imply remain part of the lived reality for people trying to come off antidepressants when clinical support is limited [Wired, June 2025] [Business Insider, October 2026]. Outro's place in that landscape is narrower and more legible: a virtual, paid, clinician-guided taper management service built specifically around antidepressant deprescribing, later expanding beyond that wedge according to funding-announcement coverage [MobiHealthNews, October 2026] [Citybiz, October 2026].
Its edge today appears to be domain specificity rather than scale. Public reporting ties the company closely to Dr. Mark Horowitz's work on antidepressant withdrawal and hyperbolic tapering, and the product description consistently emphasizes personalized taper plans, monitoring, and dose adjustment rather than generic mental health visits [Wired, June 2025] [outro.com] [MobiHealthNews, October 2026]. That gives Outro a real positioning advantage with patients actively seeking deprescribing support, especially because the service was reported as available in 14 states by October 2026 after launching in seven states in 2025 [prweb.com, May 2025] [Citybiz, October 2026]. The harder question is durability. Clinical reputation and focused protocol design can persist, but geographic coverage, clinician supply, and workflow tooling are perishable advantages if larger telehealth groups, health systems, or existing psychiatric practices decide to package similar taper-support offerings around their existing patient bases [Wired, June 2025] [Morningstar, October 2026].
The exposure is equally clear. Outro does not appear, from public evidence, to own a privileged distribution channel such as employer benefits, payer reimbursement, or a large enterprise partnership base, and the available reporting identifies no named institutional customers [MobiHealthNews, October 2026]. Price also cuts both ways. Wired reported entry pricing starting at $125 per month, which is low enough to broaden consumer access but may leave limited room to absorb acquisition costs, state-by-state clinical operations, and compounded-medication coordination if retention is uneven or care duration runs long [Wired, June 2025]. The strongest substitute is therefore not a named startup in the source set, but ordinary prescriber relationships that already sit inside patients' existing care pathways. If a patient's current psychiatrist is willing and able to supervise a taper, Outro has to win on specialization and convenience rather than access alone [Wired, June 2025].
The most plausible 18-month scenario is a category-shaping one rather than a winner-take-all startup fight. Winner if X: Outro, if it can turn its antidepressant tapering niche into a broader deprescribing brand while expanding state coverage and clinician capacity faster than incumbents formalize equivalent programs [Citybiz, October 2026] [Morningstar, October 2026]. Loser if Y: self-directed tapering communities and informal workarounds, if clinically supervised virtual taper programs become easier to access and more trusted by patients who currently rely on nonclinical guidance [Business Insider, October 2026] [Wired, June 2025]. The reverse case also deserves weight: if mainstream psychiatry and primary care absorb hyperbolic tapering practices into routine care without needing a dedicated intermediary, Outro's differentiation could narrow from category creator to feature-level service line.
One source, partially checked -- Competitive framing is supported by Wired, MobiHealthNews, Citybiz, Morningstar, and Outro's website, but the section lacks named startup competitors in the source set and therefore relies partly on category-level inference from public reporting.
Opportunity
PUBLIC
The prize, if execution holds, is larger than a niche telehealth clinic: Outro could become the default care layer for psychiatric medication deprescribing in the U.S., starting with antidepressants and then extending into adjacent drug classes as clinical protocols, prescriber supply, and patient trust accumulate [Morningstar, October 2026] [MobiHealthNews, October 2026].
The clearest upside case starts with an unusually specific wedge. Outro is not selling general mental health support, and it is not presenting as a broad primary care platform. Public reporting describes a focused service that helps patients reduce antidepressant doses through clinician-guided tapering, ongoing monitoring, and personalized plans, with service initially priced from $125 per month and launched across seven states by mid-2025 before reaching 14 states by October 2026 [Wired, June 2025] [prweb.com, May 2025] [Citybiz, October 2026]. That matters because narrow clinical focus can be an advantage when patient need is persistent, existing care pathways are fragmented, and trust depends on specialized expertise. The evidence is still early, but the company has shown enough geographic expansion and financing support to make a category-leading outcome reachable rather than purely theoretical [Morningstar, October 2026] [Citybiz, October 2026].
The paths to scale are visible even if none is yet proven. The table below frames three ways the company could move from a direct-to-consumer telehealth service into a larger platform position.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Specialist telehealth leader | Outro becomes the best-known national provider for antidepressant taper management, expanding state coverage and clinician capacity until it is the default referral destination for complex SSRI discontinuation cases | Continued clinician-network buildout funded by the October 2026 financing and steady expansion beyond the 14-state footprint reported in October 2026 [Morningstar, October 2026] [Citybiz, October 2026] | The company already moved from a seven-state launch in 2025 to 14 states by October 2026, suggesting operational expansion rather than a static pilot [prweb.com, May 2025] [Citybiz, October 2026] |
| Protocol platform for deprescribing | Outro extends from antidepressants into additional psychiatric or related medication classes, using its taper-management workflows as a repeatable clinical product | Product extension beyond antidepressants, which management tied directly to the new funding round [Morningstar, October 2026] [Pulse 2.0, October 2026] | Public sources say the company currently offers antidepressant taper management and intends to broaden to other drug classes, which is a more credible expansion path than launching into unrelated care lines [outro.com] [Morningstar, October 2026] |
| Workflow and evidence engine | Outro develops software and operational tooling that make tapering safer, easier to supervise, and easier to standardize across a broader clinician network | Investment in AI-assisted clinical workflows and partnerships with universities and advocacy groups, as described in the funding announcement [Morningstar, October 2026] [Citybiz, October 2026] | If the care model produces structured monitoring and dose-adjustment data over time, software could become more valuable to the clinical service itself before it becomes a separate product. The company has already stated this workflow direction publicly [Morningstar, October 2026] [MobiHealthNews, October 2026] |
What compounding could look like is fairly straightforward. More patients generate more observations on taper timing, symptom monitoring, and dose-adjustment patterns inside a narrow use case; better protocols and smoother workflows can then support more clinicians across more states, which in turn broadens access and lowers acquisition friction for the next cohort [MobiHealthNews, October 2026] [Citybiz, October 2026]. This is not a classic consumer network effect, and there is no public evidence yet of a defensible data moat in the hard sense. Still, there is a plausible service flywheel: specialist reputation attracts patients, patient volume supports clinician specialization, specialization improves outcomes and confidence, and that credibility makes expansion into adjacent deprescribing categories more credible [Wired, June 2025] [Morningstar, October 2026]. Dr. Mark Horowitz's public profile in antidepressant withdrawal research strengthens that loop because credibility in this category is clinical before it is technical [outro.com] [luma.com].
The size of the win depends on whether this remains a focused cash-pay clinic or evolves into category infrastructure. There is no confirmed market-size dataset in the source set, so any valuation framing has to stay conditional. In a moderate upside case, Outro becomes the national specialist brand in antidepressant tapering and adjacent deprescribing care, with value anchored in a scaled virtual clinic and proprietary care workflows. In a stronger upside case, the company uses the October 2026 financing to build a repeatable protocol and workflow layer that can extend beyond one medication category and support a much larger clinician network [Morningstar, October 2026] [Pulse 2.0, October 2026]. If that second scenario plays out, the asset begins to resemble a category platform rather than a single-service clinic, which could support venture-scale outcomes in healthtech (scenario, not a forecast). The public evidence does not yet support a hard valuation range, but it does support the more basic point that Outro is aiming at a care problem large enough, painful enough, and specialized enough to justify a national platform attempt [Wired, June 2025] [Business Insider, October 2026].
One source, partially checked -- Core claims in this section are supported by named public sources including Morningstar, Citybiz, Wired, MobiHealthNews, and outro.com, but the scenario analysis and platform compounding logic remain analytical inferences rather than observed outcomes.
Sources
Publicly reported
[Morningstar, October 2026] Outro Announces $7M in Funding to Expand Access to Safe Deprescribing, Starting With Antidepressants | https://www.morningstar.com/news/business-wire/20261008574189/outro-announces-7m-in-funding-to-expand-access-to-safe-deprescribing-starting-with-antidepressants
[Wired, June 2025] ‘Uber for Getting Off Antidepressants’ Launches in the US | https://www.wired.com/story/tapering-off-anti-depressants-outro-telehealth/
[MobiHealthNews, October 2026] Outro raises $7M for antidepressant tapering | https://www.mobihealthnews.com/news/outro-raises-7m-antidepressant-tapering
[Citybiz, October 2026] Outro Raises $7 Million to Expand Antidepressant Deprescribing Platform | https://www.citybiz.co/article/916074/outro-raises-7-million-to-expand-antidepressant-deprescribing-platform/
[outro.com, retrieved 2026] Mark Horowitz, MD, PhD, Co-Founder | https://www.outro.com/about/bio/mark-horowitz-md-phd
[luma.com, retrieved 2026] Mark Horowitz | https://lu.ma/
[success.ai, retrieved 2026] Brandon Goode | https://www.success.ai/
[marketscreener.com, retrieved 2026] Tyler Dyck | https://www.marketscreener.com/
[Pulse 2.0, October 2026] Outro Raises $7 Million To Expand Deprescribing Platform Beyond Antidepressants | https://pulse2.com/outro-raises-7-million/
[Business Insider, October 2026] As a nurse in the antidepressant 2.0 era, I'm teaching my patients to cut down their doses using jewelry scales | https://www.businessinsider.com/outro-deprescribing-clinic-raises-7-million-2026-10
[Crunchbase] OUTRO - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/outro
[Wikipedia, retrieved 2026] Mark Abie Horowitz - Wikipedia | https://en.wikipedia.org/wiki/Mark_Abie_Horowitz
Articles about Outro
- Outro Health's Virtual Clinic Targets a Gap in Psychiatric Care — The New York startup is scaling a virtual care model for safely reducing psychiatric medications, starting with SSRIs, after raising capital from Listen Ventures and LAUNCH.